In a video interview with Pharma Commerce, Derrick Gastineau, Head of Marketing with Currax Pharmaceuticals, emphasizes the importance of pricing consistency in improving access, affordability, and long-term adherence to obesity treatments, particularly with FDA-approved oral weight loss drugs. He explained that one of the primary frustrations patients face is the unpredictability of out-of-pocket costs. This uncertainty can deter patients from initiating treatment altogether, as they may lack confidence in their ability to sustain the therapy financially over the long term.
Gastineau noted that consistency in pricing addresses this barrier by offering patients a predictable and manageable financial pathway to care. Programs designed to provide reliable cash-pay options, such as those facilitated through mail-order pharmacies, help patients integrate treatment costs into their budgets with greater confidence. This assurance is particularly important in the case of chronic conditions like obesity, where ongoing treatment is essential to achieving meaningful health outcomes.
By stabilizing the cost of therapy, such programs not only improve access but also support adherence. Patients are more likely to stay committed to their medication regimen when they know that affordability will not suddenly become an obstacle. This has significant implications for long-term health benefits, as consistent therapy can lead to better outcomes and reduced overall healthcare costs.
Gastineau highlighted that obesity, like many chronic diseases, requires a long-term treatment approach. Ensuring patients have uninterrupted access to affordable medication is therefore a critical factor in driving sustainable health improvements. In this context, consistent cash-pay programs are not merely financial tools but essential components of chronic disease management.
Ultimately, Gastineau framed the issue as one of equity and sustainability: when patients can rely on steady, affordable access to medications, they are more empowered to take charge of their health and achieve lasting results in managing obesity.
He also described what makes treatment options an attractive alternative from both a clinical and patient experience standpoint; how marketers can effectively communicate the safety and regulatory advantages of approved therapies over compounded or off-label treatments in the weight management space; and what needs to be done to combat bad actors in the sector?
A transcript of his conversation with PC can be found below.
PC: How could a consistent cash-pay option for an FDA-approved oral weight loss drug improve access, affordability, and long-term adherence in obesity care?
Gastineau: Consistency is the key word in that question. We’ve heard resoundingly from patients that uncertainty around out-of-pocket prices for medications—particularly when we’re talking about obesity medications—is one of the biggest frustrations, and sometimes can even be a barrier from a patient even starting a medication if they aren’t confident that they’re going to be able to afford it and stay on therapy long term.
By providing programs like this, as well as our Cure Access program that we offer via our mail- order pharmacies that we work with, that provides patients with the reassurance that they’re going to have access to the medication at a consistent, affordable price that fits into their life and their individual financial situation, and that’s critical when it comes to chronic diseases like obesity, where continuing treatment is critical for the long-term health and outcomes for the patient.